Concepedia

Satoshi Tamada

ST

Statistics

Publications

47

Citations

6.7K

H-Index

27

Active since

2002

Affiliations

Osaka City University(Current)

Queen Mary University of London

Merck & Co., Inc., Rahway, NJ, USA (United States)

Université Laval

Barts Health NHS Trust

Satoshi Tamada is an author at Osaka City University specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2002–2025

47

Publications

47

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

, , +9

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 745 citations

, , +13

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

, , +14

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

, , +16

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Elizabeth R. Plimack, Thomas Powles, V.P. Stus et al. · European Urology · 2023 · 137 citations

, , +12

1–5 of 47